Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment

Leukemia Research

Volumn 37, Issue 8, 2013, Pages 889-893

  Douvali, Evdoxia ^a   Papoutselis, Menelaos ^a   Vassilakopoulos, Theodoros P ^b   Papadopoulos, Vasileios ^c   Spanoudakis, Emmanouil ^a   Tsatalas, Costas ^a   Kotsianidis, Ioannis ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

5 azacytidine; CKD; MDS; Renal impairment

Indexed keywords

AZACITIDINE;

ADULT; AGED; ARTICLE; BLEEDING; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; INFECTION; KIDNEY FUNCTION; MALE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INFECTION; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; REMISSION INDUCTION; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84879784476     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.05.005     Document Type: Article

References (22)

1. Garcia-Manero G., Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 2011, 29:516-523.
2. Santini V. Novel therapeutic strategies: hypomethylating agents and beyond. Hematology (Am Soc Hematol Educ Program) 2012, 2012:65-73.
3. Ades L., Itzykson R., Fenaux P. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine. Semin Hematol 2012, 49:323-329.
4. Tefferi A., Vardiman J.W. Myelodysplastic syndromes. N Engl J Med 2009, 361:1872-1885.
5. Marcucci G., Silverman L., Eller M., Lintz L., Beach C.L. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 2005, 45:597-602.
6. Palm P.E.K.C. Preclinical toxicology of NSC-102816 (5-azacytidine) in mice, hamsters, and dogs. US Clearing House Fed Sci Tech Inform PB Rep 1970, 194791.
7. Peterson B.A., Collins A.J., Vogelzang N.J., Bloomfield C.D. 5-Azacytidine and renal tubular dysfunction. Blood 1981, 57:182-185.
8. Von Hoff D.D., Slavik M., Muggia F.M. 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med 1976, 85:237-245.
9. Nadasi E., Clark J.S., Szanyi I., Varjas T., Ember I., Baliga R., et al. Epigenetic modifiers exacerbate oxidative stress in renal proximal tubule cells. Anticancer Res 2009, 29:2295-2299.
10. Arany I., Clark J.S., Ember I., Juncos L.A. Epigenetic modifiers exert renal toxicity through induction of p66shc. Anticancer Res 2011, 31:3267-3271.
11. Baumgarten M., Gehr T. Chronic kidney disease: detection and evaluation. Am Fam Physician 2011, 84:1138-1148.
12. Lichtman S.M. Guidelines for the treatment of elderly cancer patients. Cancer Control 2003, 10:445-453.
13. Batty G.N., Kantarjian H., Issa J.P., Jabbour E., Santos F.P., McCue D., et al. Feasibility of therapy with hypomethylating agents in patients with renal insufficiency. Clin Lymphoma Myeloma Leuk 2009, 10:205-210.
14. Tsao C.F., Dalal J., Peters C., Gonzalez C., Kearns G.L. Azacitidine pharmacokinetics in an adolescent patient with renal compromise. J Pediatr Hematol Oncol 2007, 29:330-333.
15. Demirovic J.A., Pai A.B., Pai M.P. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009, 66:642-648.
16. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
17. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
18. Na S.Y., Sung J.Y., Chang J.H., Kim S., Lee H.H., Park Y.H., et al. Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality. Am J Nephrol 2011, 33:121-130.
19. Breccia M., Salaroli A., Loglisci G., Finsinger P., Serrao A., Alimena G. MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine. Haematologica 2012, 97:e2.
20. Della Porta M.G., Malcovati L., Strupp C., Ambaglio I., Kuendgen A., Zipperer E., et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica 2011, 96:441-449.
21. Greenberg M.S. Reversible renal dysfunction due to 5-azacytidine. Cancer Treat Rep 1979, 63:806.
22. Voso M.T., Fianchi L., Criscuolo M., Greco M., D'Alo F., Hohaus S., et al. Azacitidine in a patient with myelodysplastic syndrome: impact of switching from a 5-day to the approved 7-day dosing schedule. Leuk Res 2012, 36:e15-e17.